

# INDEX

## A

- Adeno-associated viruses (AAV)..... 363  
 Adenosine A<sub>2A</sub> receptor (Adora2a)..... 58, 59,  
 61, 62, 66–71, 74, 75  
 Aggregation..... 34, 195, 284, 289, 297–299  
 Aggresome..... 289–291, 294, 295, 297, 299, 301  
 Agonist  
   allosteric..... 105, 111  
   biased..... 151  
   orthosteric..... 9, 105, 127, 178, 179  
 Amido black 10B protein assay..... 38, 46, 48  
 Analgesia..... 352, 354  
 Antibody..... 86, 91, 94, 95,  
 99, 100, 207, 269–272, 277, 281, 282, 291,  
 295, 301, 307, 319, 320, 325, 326, 328, 330,  
 334, 335, 340, 341, 345, 346, 363–366, 373,  
 398  
 Apo-state..... 33, 34, 47  
 Autoradiography..... 66, 67, 69, 70, 72, 75

## B

- Bacterial transcription factor  $\tau$ TA..... 258  
 $\beta$ -Arrestin..... 257–266, 323, 324  
 Bimolecular fluorescence complementation  
   (BiFC)..... 199–214  
 Binding..... 4, 5, 7, 8, 10, 34–36,  
 49, 57, 68, 82, 95, 96, 101, 103, 105–107,  
 110, 111, 119, 127, 128, 130, 138, 151, 153,  
 156, 157, 159–167, 170, 183, 218, 245, 257,  
 318, 323, 339  
 Bioluminescence  
   *ex vivo*..... 362, 364, 369–371  
   imaging..... 366, 369  
   *in vitro*..... 369  
   *in vivo*..... 362, 366–369  
 Bioluminescence resonance energy transfer (BRET)  
   acceptor:donor ratio (A:D)..... 184  
   BRET<sup>2</sup>..... 200–202,  
   204, 207–210, 213, 214  
    $\Delta$ BRET..... 178, 179  
   efficiency (BRET<sub>eff</sub>)..... 184,  
   185, 188, 190–197, 208, 214  
   saturation assays..... 184, 213

- type-1 assays..... 184, 185,  
   187, 188, 193, 194  
   type-2 assays..... 184, 185, 188, 193, 194  
   type-3 assays..... 184, 185, 187,  
   188, 193, 195–197

## C

- cAMP..... 131, 217, 219, 220,  
 227–231, 258, 345, 362, 364, 367, 369, 371,  
 374, 389, 391  
 Cell-based assays..... 258  
 Cell culture  
   transfection  
     lipofectamine..... 113, 115,  
     173, 207, 276, 281, 306, 308, 340, 341  
 Cell-free protein synthesis  
   amber suppression..... 61  
   microsomes..... 58  
   non-canonical amino acid..... 58, 69  
   protein modification..... 58  
 Cerebral blood flow (CBF)..... 377–386  
 Chemical cross-linking..... 82, 83  
 Chemical ligation..... 32, 138  
 Chinese hamster ovary cells (CHO)..... 58, 61,  
 65, 73, 74, 118, 157, 159, 163, 219, 232, 233  
<sup>13</sup>CH<sub>3</sub>-methionine..... 31, 43, 46, 47  
 Clozapine N-oxide (CNO)..... 105, 362,  
 364, 366, 372, 373  
 Coelenterazine-400A..... 186, 190, 196  
 Coelenterazine h..... 173, 176, 177,  
 180, 181, 186, 192, 196  
 Co-immunoprecipitation (co-IP)..... 200,  
 270, 274, 277, 280, 281, 283  
 Computational analysis..... 390  
 Confocal laser scanning microscopy  
   image analysis..... 292  
   image processing..... 292, 296, 297, 311  
   Z-stack acquisition..... 311  
 Conformation-sensitive biosensors..... 170–172, 176  
 Constitutively active Rab5 (Rab5-Q79L)..... 304,  
 305, 308  
 CREB luciferase reporter..... 366, 368, 369, 371, 374  
 CRISPR/Cas9..... 111, 169–182

**D**

Designer receptors exclusively activated by designer drugs (DREADDs) ..... 105, 361–374  
D-luciferin ..... 260, 265, 364, 366, 371, 374  
Dose–response curve ..... 129, 131, 224, 233, 234  
Drug discovery ..... 82, 169, 170, 352

**E**

EC<sub>50</sub> ..... 218–220, 222, 224, 226, 228–231, 233, 235  
Electrophoresis  
    Laemmli sample buffer ..... 274  
    PVDF membrane ..... 89, 95, 364  
    SDS-PAGE ..... 49, 85, 89, 94, 274  
Electrophysiology  
    G protein-coupled Inward Rectifying Potassium Channel (GIRK1) ..... 121  
    whole cell patch clamp ..... 117–119  
Endocytosis ..... 324  
Endosomes ..... 303–305, 308, 309, 311–314, 319–321, 324  
Enhanced orthogonal aminoacyl-tRNA-synthetase ..... 59, 60, 63, 64  
*Escherichia coli* (*E. coli*) ..... 31–52, 58, 59, 63, 120, 205, 206

**F**

FLaSH ..... 170, 171, 173–181  
Fluorescence resonance energy transfer (FRET)  
    R<sub>0</sub> ..... 152, 219–222, 224, 228, 229, 231, 233  
    R<sub>max</sub> ..... 219–222, 224, 226, 228, 229, 231, 232  
    R<sub>min</sub> ..... 219, 222, 226, 228–231, 233, 234  
    time-resolved (TR-FRET) ..... 137–145, 151–167  
Fluorescent labeling  
    bodipy-TMR-lysine ..... 65–67, 72  
    in-gel fluorescence ..... 66, 67, 70–72  
Fluorescent ligands ..... 152, 154–156, 161, 166, 319  
Fluorescent probes ..... 137–145  
Fluorophore characterization ..... 326, 330–333  
Furan ..... 81–101  
Fusion proteins ..... 33, 34, 43–45, 49, 50, 66, 213, 214, 258

**G**

Genome editing ..... 111, 171, 172, 178, 180  
Glo reagent ..... 260, 262, 265  
Glutathione Sepharose ..... 39, 44, 50, 245, 247  
G protein-coupled receptors (GPCRs) ..... v, 3–16, 21–29, 31, 57–75, 81–101, 103–132, 137–145, 151–167, 169–183, 199–214, 241, 249, 257, 259, 262, 264, 269–271, 282–284,

289, 297–299, 304, 323–346, 351, 361–374, 377–386, 389–401

Green fluorescent protein (GFP) ..... 49, 121, 155, 183, 200, 311, 365  
Ground state depletion microscopy (GSDM) ..... 323–336  
G<sub>s</sub> ..... 131  
GST-tagged HRV 3C protease ..... 39, 44, 50

**H**

HeLa cells ..... 99, 118  
Hill coefficient ..... 218–220, 224, 226, 228–231, 233, 235  
His<sub>10</sub>-tag ..... 34–36, 43, 45  
HTLA cells ..... 260, 265  
HTRF® ..... 153, 156, 157  
Human delta opioid receptor (DOPr) ..... 290, 298, 305  
Human embryonic kidney 293 (HEK293) ..... 99, 157–159, 163, 233, 253, 265, 269–271, 276, 277, 290–294, 297, 304, 305, 308, 327, 334, 339, 340  
Human embryonic kidney 293 T (HEK293T) ..... 260  
Hydrazinopeptides ..... 137–145

**I**

Imidazole removal ..... 43, 44  
Immobilized metal-affinity chromatography (IMAC) ..... 34, 38, 39, 41, 43–46, 49  
Immunofluorescence ..... 320  
Intraluminal vesicles (ILVs) ..... 303–305, 311  
IRDye 680 Streptavidin ..... 86, 91  
Isopropyl β-D-1-thiogalactopyranoside (IPTG) ..... 33, 37, 41, 59, 63

**K**

Knock-In ..... 361–374

**L**

Lanthanides ..... 139, 153–155, 163  
Laser doppler flowmetry (LDF) ..... 377–386  
Liquid chromatography ..... 84, 279  
Localization microscopy ..... 337–346  
Luciferase  
    *Renilla* luciferase II (RlucII) ..... 170, 176–178

**M**

Mass spectrometry ..... 269, 271–274  
MDA-MB-231 cells ..... 83, 89, 93, 99  
Membrane proteins ..... 57, 58, 67, 69, 115, 137, 151, 289

Metabotropic glutamate (mGluRs) receptors	
mGluR2 receptors.....	106, 108, 112, 117, 119–121, 123–127, 129
mGluR3 receptors.....	106, 108
mGlu <sub>5</sub> receptor.....	352
mGluR6 receptors.....	106, 108, 120, 209, 212, 213
Microplate	
reader.....	63, 158, 164, 181
Misfolding.....	298
Molecular dynamics	
communication networks.....	7
conformational ensemble.....	7, 10
Markov State Model.....	8, 15
multiscale modeling.....	5
root mean square deviations (RMSDs).....	24, 25
water permeation.....	21
Mouse.....	112, 184, 219, 221, 230, 275, 281, 291, 297, 340, 353, 354, 356, 358, 362–366, 368–371, 374, 379, 381–384, 386
Multivesicular bodies (MVBs).....	303
Myography.....	391, 393, 394, 396–398
<b>N</b>	
NanoLuciferase (Nluc).....	59, 61, 66
Neuromodulation.....	103
Neurotensin receptor 1 (NTS1).....	31
Neurovascular coupling (NVC).....	378, 383, 386
Nuclear magnetic resonance (NMR).....	31
<b>O</b>	
Oligomerization	
hetero-oligomerization.....	157, 160
homo-oligomerization.....	151, 157, 160
Optogenetics.....	103
Optopharmacology.....	351, 352
<b>P</b>	
Pain.....	4, 352, 381
Photoactivatable dyes (PD)	
CAGE dyes.....	340, 341, 345
Photoactivated localization microscopy	
PD-PALM.....	338–345
Photoswitchable orthogonal remotely tethered ligands (PORTLs).....	103–132
Physiology.....	v, 3, 5, 57, 98, 103, 104, 106, 112, 118, 126, 151, 169, 184, 213, 303, 338, 352, 354, 361, 373, 378, 380, 385, 389, 400
Poly-L-lysine (PLL).....	113, 115, 259, 261, 262, 265, 291, 294, 300, 306, 309, 316, 334
Polymerase chain reaction (PCR).....	60, 64, 65, 73, 170, 187, 206, 213
Post-endocytic sorting.....	303
Prokaryotic expression.....	63
Protein purification.....	37–39
Protein-tyrosine phosphatase (PTP)	
colorimetric phosphatase assay.....	241, 249
in-gel phosphatase assay.....	241, 249
phosphatase activity.....	242, 243
Proteome.....	v
PROTEOSTAT®.....	290, 291, 294, 297, 299
Pulmonary artery.....	389–401
<b>R</b>	
Rat.....	33, 35, 219, 233, 272, 275, 277, 379
Reactive oxygen species (ROS).....	89, 93, 100
Real time imaging.....	170, 217
Rhodopsin.....	3, 21–23, 25–27, 29, 32, 81, 105, 289
Rodent.....	352, 377–386
<b>S</b>	
Scintillation counting.....	66, 67, 69, 72
Self-labeling enzyme.....	155, 160, 164, 165
Sequential BRET2-FRET (SRET2).....	200, 301
Signaling.....	v, 5, 8, 9, 35, 47, 57, 81, 103–105, 121, 131, 137, 241–244, 258, 303, 305, 323, 324, 361–374, 378, 389–391, 397
Silencing RNA (siRNA).....	305, 306, 308, 309, 311, 313, 316, 318
Singlet oxygen.....	93, 100
Size exclusion chromatography (SEC).....	34, 39, 43, 45, 46, 50
Smooth muscle cells.....	390, 391
SNAP tag.....	107, 110–113, 115, 116, 120, 121, 127, 130, 131, 155, 159, 164, 165
Solid phase peptide synthesis (SPPS).....	83, 86, 92
Spatial assembly.....	337–346
Spectrophotometer.....	85, 98, 100, 113, 122, 123, 254
Stoichiometry.....	124, 183–197, 337–339
Super-resolution microscopy.....	323–336, 338, 339, 341, 344
Suppressor tRNA.....	58–61, 64–65, 68
<b>T</b>	
Tagged receptors.....	127, 130, 131, 158, 166, 184
Tag-lite® screening.....	152, 158–161, 164
TALON® slurry.....	41, 44
Tamoxifen.....	363, 365

Tango .....	257, 259, 262, 264	Translocation .....	69, 258
Terbium .....	139, 153–155, 393, 395	<b>V</b>	
Tethered ligands, <i>see</i> PORTLs		Vasoconstriction .....	390, 391
Tetracysteine tag .....	170, 171	<b>W</b>	
Thermostable .....	31, 35	Western blots .....	82, 85, 88, 89, 94–97, 99, 100, 249, 251, 254, 270, 271, 274–277, 280–283, 300, 319, 320, 364–366, 373
3C protease cleavage .....	34, 36, 43, 44	Whisker stimulation .....	383, 386
Tissue			
specific activation.....	361–374		
temporal activation.....	361–374		
tissue perfusion units (TPU).....	383, 386		
Tobacco etch virus protease cutting site (TEVcs).....	258		
Transactivator (tTA)-driven luciferase .....	260		